The stock has a 36-month beta value of 0.99. Opinions on the stock are mixed, with 2 analysts rating it as a “buy,” 2 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for PSTV is 16.57M, and at present, short sellers hold a 7.55% of that float. On April 23, 2025, the average trading volume of PSTV was 16.26M shares.
PSTV) stock’s latest price update
Plus Therapeutics Inc (NASDAQ: PSTV)’s stock price has plunge by 22.78relation to previous closing price of 0.64. Nevertheless, the company has seen a 23.06% surge in its stock price over the last five trading sessions. globenewswire.com reported 2025-04-15 that New abstract published ahead of the Nuclear Medicine and Neurooncology Conference shows promise for REYOBIQ New abstract published ahead of the Nuclear Medicine and Neurooncology Conference shows promise for REYOBIQ
PSTV’s Market Performance
Plus Therapeutics Inc (PSTV) has seen a 23.06% rise in stock performance for the week, with a -33.31% decline in the past month and a -36.53% plunge in the past quarter. The volatility ratio for the week is 21.04%, and the volatility levels for the past 30 days are at 19.84% for PSTV. The simple moving average for the past 20 days is -12.84% for PSTV’s stock, with a -38.77% simple moving average for the past 200 days.
Analysts’ Opinion of PSTV
Many brokerage firms have already submitted their reports for PSTV stocks, with D. Boral Capital repeating the rating for PSTV by listing it as a “Buy.” The predicted price for PSTV in the upcoming period, according to D. Boral Capital is $9 based on the research report published on March 17, 2025 of the current year 2025.
Ladenburg Thalmann, on the other hand, stated in their research note that they expect to see PSTV reach a price target of $8. The rating they have provided for PSTV stocks is “Buy” according to the report published on January 25th, 2021.
Maxim Group gave a rating of “Buy” to PSTV, setting the target price at $6 in the report published on October 16th of the previous year.
PSTV Trading at -18.44% from the 50-Day Moving Average
After a stumble in the market that brought PSTV to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -70.53% of loss for the given period.
Volatility was left at 19.84%, however, over the last 30 days, the volatility rate increased by 21.04%, as shares sank -30.96% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -36.35% lower at present.
During the last 5 trading sessions, PSTV rose by +23.06%, which changed the moving average for the period of 200-days by -48.56% in comparison to the 20-day moving average, which settled at $0.9029. In addition, Plus Therapeutics Inc saw -31.57% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at PSTV starting from Hawkins Richard J, who purchase 4,000 shares at the price of $1.50 back on Sep 13 ’24. After this action, Hawkins Richard J now owns 15,188 shares of Plus Therapeutics Inc, valued at $5,996 using the latest closing price.
Hawkins Richard J, the Director of Plus Therapeutics Inc, purchase 6,285 shares at $1.35 during a trade that took place back on Sep 12 ’24, which means that Hawkins Richard J is holding 11,188 shares at $8,512 based on the most recent closing price.
Stock Fundamentals for PSTV
Current profitability levels for the company are sitting at:
- -4.97 for the present operating margin
- -0.0 for the gross margin
The net margin for Plus Therapeutics Inc stands at -4.39. The total capital return value is set at 1.65.
Based on Plus Therapeutics Inc (PSTV), the company’s capital structure generated -0.6 points at debt to capital in total, while cash flow to debt ratio is standing at -3.13. The debt to equity ratio resting at -0.38. The interest coverage ratio of the stock is -3.95.
When we switch over and look at the enterprise to sales, we see a ratio of 5.64. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.31.
Conclusion
To sum up, Plus Therapeutics Inc (PSTV) has seen a bad performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
